CN111298074A - 一种预防和改善冠心病的心脏保护类的植物草药制剂 - Google Patents

一种预防和改善冠心病的心脏保护类的植物草药制剂 Download PDF

Info

Publication number
CN111298074A
CN111298074A CN201811510367.2A CN201811510367A CN111298074A CN 111298074 A CN111298074 A CN 111298074A CN 201811510367 A CN201811510367 A CN 201811510367A CN 111298074 A CN111298074 A CN 111298074A
Authority
CN
China
Prior art keywords
heart disease
coronary heart
preventing
walnut
dried pulp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811510367.2A
Other languages
English (en)
Inventor
宋元达
赛德侯赛因
李少琦
杨武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong University of Technology
Original Assignee
Shandong University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong University of Technology filed Critical Shandong University of Technology
Priority to CN201811510367.2A priority Critical patent/CN111298074A/zh
Priority to PCT/CN2019/121061 priority patent/WO2020119453A1/zh
Publication of CN111298074A publication Critical patent/CN111298074A/zh
Priority to US17/120,162 priority patent/US11077162B2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明提供了一种新的天然植物草药制剂，基于20种植物部分提取物的协同作用。它可以预防和治疗各种冠心病风险因子，包括引起心血管事件的血管炎症过程。植物提取物为以下部分：丹参鼠尾草、胡桃草、欧洲七叶树和姜的根，中国肉桂的树皮，芝麻、番木瓜、黑种草、石榴的种子，欧矢车菊的叶子，乳香黄连木树脂，椰子树的核果，可可豆，海枣的干果肉和核，油橄榄、无花果、核桃、蓝莓的干果肉，蒜瓣和蔷薇花瓣。本发明用70％乙醇在70‑80℃下处理上述植物部分并保持溶液的pH值在7‑10之间，使用色谱法和光谱法分离活性化合物并检测植物提取物的分子表征。该配方已经过试验证明具有降血脂、抗肥胖、抗动脉粥样硬化、抗氧化、抗焦虑和降低半胱氨酸的作用。该试验药物还可以改善内皮功能障碍，因此建议将其作为预防/减少不良心脏疾病的有效补救措施。

Description

一种预防和改善冠心病的心脏保护类的植物草药制剂
技术领域
本发明涉及新型天然植物草药制剂。具体涉及一种预防和改善诱发冠心病或中风的各种危险因子的方法。
背景技术
心血管疾病是发展中国家和发达国家死亡的主要原因。据世界卫生组织报告，到2020年，心脏病将成为导致残疾和死亡的主要原因。最常见的心血管疾病是冠心病，每年造成358,000多人死亡，每年花费1089亿美元。心血管疾病的诱因包括高血压，焦虑，压力，吸烟，高低密度脂蛋白胆固醇，糖尿病，超重/肥胖，不良饮食，缺乏运动和过量饮酒。尽管人们对心血管健康的补充替代医学越来越关注，但关于心血管疾病的补充替代医学的使用模式的文献较少。过去的许多研究证明，通过降低血脂水平和控制高血压，可以最大限度地减少冠心病的发病。
有大量证据证明高胆固醇血症和高甘油三酯血症会导致动脉粥样硬化，冠心病和中风。高血清胆固醇，低密度脂蛋白胆固醇和较低的高密度脂蛋白胆固醇都是导致冠心病和动脉粥样硬化发生的重要因素。高浓度的甘油三酯，小密度低密度脂蛋白胆固醇和低水平的高密度脂蛋白胆固醇被称为血脂异常，并且该过程会导致胰岛素抵抗。胰岛素抵抗综合征的特征包括许多心血管疾病诱因，如中心性肥胖，高血糖，高血压，血脂异常以及促凝血因子和炎症标志物。研究表明，通过适当管理高胆固醇血症，糖尿病患者的冠心病发生率显着减少。
急性期反应物循环细胞因子，高敏C反应蛋白，血清白蛋白和纤维蛋白原是冠心病发作和复发性急性心肌梗死的预测因子。一些研究表明，同型半胱氨酸升高在心血管疾病患者中很常见，并且极大可能会导致心脏疾病的发生。
叶酸缺乏会引起同型半胱氨酸的升高，而同型半胱氨酸的升高与心血管疾病的风险增加有关。其中一项实验研究表明，叶酸耗竭引起的高同型半胱氨酸血症会增加动脉通透性和僵硬度。升高的同型半胱氨酸水平的位置效应导致血管内皮细胞的氧化损伤，平滑肌细胞的增殖增加和动脉粥样硬化的低密度脂蛋白胆固醇高氧化。因此，它导致内皮功能障碍。同样，增加的高敏C反应蛋白在动脉粥样硬化的发病机理中起主要作用。高敏C反应蛋白和其他炎症敏感蛋白主要与斑块形态的变化和破裂和急性血栓形成有关。
研究人员已经在心力衰竭患者中证实了循环细胞因子水平升高。白细胞介素-6浓度与左心室功能障碍的严重程度和交感神经和肾素 - 血管紧张素系统的活化程度有关。因此，白细胞介素-1，IL-6和肿瘤坏死因子α的细胞因子会引起冠心病。白细胞介素-6是遗传决定的，它的水平决定了动脉粥样硬化，血栓形成和冠心病的风险。
脂联素也与血压，心率，总胆固醇，低密度脂蛋白胆固醇和甘油三酯呈负相关，与HDL-c呈正相关。研究人员认为高敏C反应蛋白，纤维蛋白原，脂蛋白和同型半胱氨酸是用于评估冠心病风险的重要生物标志物，即使在具有冠心病常规危险因素的强家族史的无症状个体中也是如此。
最近，一些生物标志物正在出现用于诊断和治疗心脏病如心肌肌钙蛋白的病理生理学，β型利钠肽是一种会引起心脏舒张的32-氨基酸反调节肽释放的物质。β型利钠肽值与年龄和急性冠状动脉综合征病例有很强的相关性。β型利钠肽升高是造成中风、阻塞性睡眠呼吸暂停、糖尿病、左侧房室性肥厚的原因。 3CD40是一种信号蛋白，它会在急性冠状动脉综合征中显着升高。
心理社会压力也在动脉高血压，心绞痛和心肌梗塞沉淀的发生中起重要作用。抑郁症是冠心病发展的独立危险因素。因此，压力管理有助于预防不良心脏事件。减少肥胖指数也有助于降低冠心病的发病率。
许多合成的常规药物疗法被用于诸如抗高血压药，抗心律失常药，降血脂药，抗糖尿病药，抗肥胖药，但它们的应用受到限制，长期使用会对生物系统产生不利影响。
发明内容
本发明提供了一种新的天然植物草药制剂，它可以预防和控制各种冠心病风险因子，包括引起心血管事件的血管炎症过程，包括70％乙醇提取植物的下列部分; 即，丹参鼠尾草、胡桃草、欧洲七叶树和姜的根，中国肉桂的树皮，芝麻、番木瓜、黑种草、石榴的种子，欧矢车菊的叶子，乳香黄连木树脂，椰子树的核果，可可豆，海枣的干果肉和核，油橄榄、无花果、核桃、蓝莓的干果肉，蒜瓣和蔷薇花瓣。
本发明还提供了一种制备植物制剂的新方法，该方法包括以下步骤：用70％乙醇在70-80℃下处理上述植物部分（表1）并保持溶液的pH值在7-10之间，使用波层色谱法，高效液相色谱法分离活性化合物，使用红外光谱和核磁共振检测植物提取物的分子表征。预防和控制各种冠心病风险因子。
表1：
<i>序列</i> 学名 组织部位 mg
<i>1</i> 丹参鼠尾草 根 20
<i>2</i> 欧矢车菊 叶 20
<i>3</i> 中国肉桂 树皮 10
<i>4</i> 胡桃草 根 10
<i>5</i> 欧洲七叶树 根 20
<i>6</i> 芝麻 种子 10
<i>7</i> 乳香黄连木 树脂 10
<i>8</i> 椰子树 核果 10
<i>9</i> 番木瓜 种子 10
<i>10</i> 黑种草 种子 20
<i>11</i> 海枣 干果肉和核 各10
<i>12</i> 核桃木 干果 10
<i>13</i> 可可 豆子 10
<i>14</i> 油橄榄 干果肉 10
<i>15</i> 无花果 干果 10
<i>16</i> 蓝莓 干果肉 10
<i>17</i> 石榴 种子 10
<i>18</i> 大蒜 蒜瓣 10
<i>19</i> 姜 根 10
<i>20</i> 突厥蔷薇 花瓣 10
[有益效果]
本发明的有益效果：本发明涉及新型植物制剂及其治疗和控制诱发冠心病或中风的各种诱因的方法。本发明的制剂用于治疗和控制血脂异常，肥胖，高血压，葡萄糖耐受不良，高半胱氨酸血症，血管炎症以及焦虑和压力。
【具体实施方式】
1提取
用去离子水彻底洗涤样品以除去任何污染物，在液氮的帮助下研磨制备粗粉末，然后用单独的乙醇，甲醇，丙酮和水提取。溶剂的选择基于它们的极性，从高到低（即水>甲醇>乙醇>丙酮），因为不同类别的生物活性化合物对不同极性的溶剂具有不同的亲和力。
为了提取，将等份的粗粉末（5g）精确称量到四个250mL烧瓶中，并与50ml乙醇，甲醇，丙酮和水一起以1:10的比例摇动过夜（16-20h）。室内温度。过夜摇动后，将所有样品以4000rpm离心10分钟，然后通过定性滤纸真空过滤上清液。然后将残余物分别再重浮于另外50ml乙醇甲醇，丙酮和水中。该过程重复两次。将合并的滤液转移到预先称重的玻璃板中，通过在40℃的热空气烘箱中放置4小时来蒸发有机溶剂，之后使用冷冻干燥装置进行滤液的冷冻干燥。冷冻干燥后，记录样品的干重并储存在-80℃下以备进一步使用。
2受试者
共有112名具有心血管病症的符合条件的受试者，随机分为两组：PHF治疗组（n = 78）和安慰剂组（n = 34） - 每日一次，含500 mg（一粒胶囊）持续12周。
3入选标准
纳入标准为35-72岁，肥胖（BMI×30 kg m-2），诊断为2型糖尿病，缺血性心脏病或高血压或高胆固醇血症或血管炎症的心血管诱因之一。
4排除标准
排除标准是对危及生命的合并症的诊断; 甲状腺疾病; 冠状动脉旁路移植术6周内;1个月内心肌梗死; 6个月内血管成形术; 左冠状动脉主干狭窄> 50％; 反应迟钝的充血性心力衰竭; 恶性不受控制的心律失常; 纯合高胆固醇血症; 严重的精神疾病; 目前酒精或药物滥用; 目前吸烟; 目前孕妇或哺乳期妇女，既往减肥手术，其他直接影响体重的病症（如铅毒性，恶性肿瘤）。
5结果
Figure 341793DEST_PATH_IMAGE002

Claims (3)

1.一种新的可以预防和控制各种冠心病风险因子的植物制剂。
2.本发明包括乙醇提取植物的下列部分：丹参鼠尾草、胡桃草、欧洲七叶树和姜的根，中国肉桂的树皮，芝麻、番木瓜、黑种草、石榴的种子，欧矢车菊的叶子，乳香黄连木树脂，椰子树的核果，可可豆，海枣的干果肉和核，油橄榄、无花果、核桃、蓝莓的干果肉，蒜瓣和蔷薇花瓣，且不局限于上述植物的各种组合搭配和提取办法。
3.根据权利要求1所述的应用，其特征在于所述的预防和控制冠心病和中风风险因子的新型天然植物草药制剂包括上述提取物。
CN201811510367.2A 2018-12-11 2018-12-11 一种预防和改善冠心病的心脏保护类的植物草药制剂 Pending CN111298074A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201811510367.2A CN111298074A (zh) 2018-12-11 2018-12-11 一种预防和改善冠心病的心脏保护类的植物草药制剂
PCT/CN2019/121061 WO2020119453A1 (zh) 2018-12-11 2019-11-26 一种预防和改善冠心病的心脏保护类的植物草药制剂
US17/120,162 US11077162B2 (en) 2018-12-11 2020-12-12 Heart-protective plant preparation for preventing and improving coronary heart disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811510367.2A CN111298074A (zh) 2018-12-11 2018-12-11 一种预防和改善冠心病的心脏保护类的植物草药制剂

Publications (1)

Publication Number Publication Date
CN111298074A true CN111298074A (zh) 2020-06-19

Family

ID=71077085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811510367.2A Pending CN111298074A (zh) 2018-12-11 2018-12-11 一种预防和改善冠心病的心脏保护类的植物草药制剂

Country Status (3)

Country Link
US (1) US11077162B2 (zh)
CN (1) CN111298074A (zh)
WO (1) WO2020119453A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103908621A (zh) * 2013-12-28 2014-07-09 新疆维吾尔药业有限责任公司 冠心病用药物及其制备方法
CN104906373A (zh) * 2015-06-03 2015-09-16 吴优 一种治疗心绞痛型冠心病的药物及其制备方法
CN105999016A (zh) * 2016-05-04 2016-10-12 安徽省雷氏农业科技有限公司 一种治疗冠心病的食疗组合物及其制备方法
CN107668695A (zh) * 2017-09-29 2018-02-09 武汉华士特工业生物技术开发有限公司 一种预防心脑血管疾病的固体营养冲剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083208A (zh) * 2007-10-01 2013-05-08 高露洁-棕榄公司 含有植物提取物的口腔组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103908621A (zh) * 2013-12-28 2014-07-09 新疆维吾尔药业有限责任公司 冠心病用药物及其制备方法
CN104906373A (zh) * 2015-06-03 2015-09-16 吴优 一种治疗心绞痛型冠心病的药物及其制备方法
CN105999016A (zh) * 2016-05-04 2016-10-12 安徽省雷氏农业科技有限公司 一种治疗冠心病的食疗组合物及其制备方法
CN107668695A (zh) * 2017-09-29 2018-02-09 武汉华士特工业生物技术开发有限公司 一种预防心脑血管疾病的固体营养冲剂及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
南朝君: "《食疗 营养与烹调》", 31 January 2014, 中国医药科技出版社 *
朱嵘: "《中国民族医药特色诊疗技术年鉴.2013卷》", 31 July 2014, 中国中医药出版社 *
杨卫平等: "《新编中草药图谱及经典配方.4》", 31 May 2014, 贵州科技出版社 *
赵中振等: "《当代药用植物典.3》", 30 September 2018, 上海世界图书出版公司 *

Also Published As

Publication number Publication date
US20210093688A1 (en) 2021-04-01
US11077162B2 (en) 2021-08-03
WO2020119453A1 (zh) 2020-06-18

Similar Documents

Publication Publication Date Title
Jeon et al. The effect of aronia berry on type 1 diabetes in vivo and in vitro
Rezaei-Nasab et al. Gastroprotective effects of aqueous and hydroalcholic extract of Scrophularia striata on ethanol-induced gastric ulcers in rats
TW201609123A (zh) 五層龍屬組成物、藉由其投藥之治療方法及其製備方法
Saryono et al. Anti-inflammatory effect of date seeds (Phoenix dactylifera L) on carrageenan-induced edema in rats
Ravi The active compounds of Passiflora spp and their potential medicinal uses from both in vitro and in vivo evidences
KR20230088290A (ko) 사철쑥 및 죽순 추출물을 포함하는 장질환 예방 또는 치료용 조성물
KR20160081814A (ko) 옥수수 추출물의 추출 방법 및 상기 옥수수 추출물을 포함하는 기능성 조성물
CN111298074A (zh) 一种预防和改善冠心病的心脏保护类的植物草药制剂
KR100948281B1 (ko) 식물생약제를 이용한 추출물로된 다이어트용 식품의 제조방법
Al-Shaibani et al. The Effect of Zizyphus spina-christi Extracts on hyperglycemia induced by hyperlipidemic diet in Albino rats
KR20190084927A (ko) 흑무(Raphanus sativus L. var niger) 추출물을 유효성분으로 포함하는 비만 또는 지방간의 예방 또는 치료용 조성물
KR20130121321A (ko) 돼지감자 지상부 추출물을 유효성분으로 함유하는 항염 조성물
Maryam et al. Effect of ethanolic leaf extract of Senna fistula on some haematological parameters, lipid profile and oxidative stress in alloxan-induced diabetic rats
CD et al. Effect of some phytochemicals extracted from goat’s rue (Galega officinalis) on some biochemical parameters in normal and alloxan-induced diabetic rats
Sinha et al. Hypoglycemic Activity of Carica papaya Leaf Aqueous Extract in Normal and Diabetic Mice
Jindal et al. Isolation, characterization and evaluation of anti-proliferative properties of andrographolide isolated from on cultured HaCaT cells
KR20070068837A (ko) 영실로부터 얻은 지방세포분화 억제용 활성 분획 조성물
Goh et al. Assessment of the Effects of an Aqueous Extract of the Leaves, Flowers, and Seeds of Crotalaria retusa L (Fabaceae) on the Glycemia in Rats
KR20190030052A (ko) 흑무(Raphanus sativus L. var niger) 추출물을 유효성분으로 포함하는 비만 또는 지방간의 예방 또는 치료용 조성물
Aison et al. A Systematic Review on the Antihyperglycemic Property and Effect of Roselle (Hibiscus sabdariffa Linn.) Fruit Peel Extract in Diabetic Male Rats (Rattus norvegicus) Induced by Streptozotocin
KHAN et al. Isolation of caccigenin and investigation of anti-diabetic properties of tropical almond (Terminalia schimperiana) root bark extracts on albino rats
Alhabeeb et al. The protective effect of Moringa olifera against complications of type2 diabetes mellitus in male albino rats.: Effect of Moringa olifera on Diabetes
BHAVA et al. Screening of Antidiabetic Activity of Delonix Elata Whole Plant Extracts in Diabetic Wistar Rats.
US10905703B2 (en) Preparation of a composition containing stilbene glycoside
KR101305090B1 (ko) 관절용 초본 제제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200619